Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: Relationship to early cognitive dysfunction and late depression

Reviews in the Neurosciences

Volumn 23, Issue 5-6, 2012, Pages 681-690

  Hauer, Daniela ^a   Weis, Florian ^a   Campolongo, Patrizia ^b   Schopp, Mirjam ^a   Beiras Fernandez, Andres ^a,c   Strewe, Claudia ^a   Giehl, Markus ^a   Toth, Roland ^a,d   Kilger, Erich ^a   Schelling, Gustav ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c GOETHE UNIVERSITY   (Germany)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cardiac surgery; Delirium; Depression; Endocannabinoids; Glucocorticoids

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; HYDROCORTISONE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEART SURGERY; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SURGICAL PATIENT;

AGED; ARACHIDONIC ACIDS; COGNITION DISORDERS; DEPRESSION; DOUBLE-BLIND METHOD; ENDOCANNABINOIDS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GLYCERIDES; HEART DISEASES; HUMANS; HYDROCORTISONE; LURIA-NEBRASKA NEUROPSYCHOLOGICAL BATTERY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYUNSATURATED ALKAMIDES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; STATISTICS, NONPARAMETRIC;

EID: 84869402849     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2012-0058     Document Type: Article

References (53)

1. Atsak, P., Hauer, D., Campolongo, P., Schelling, G., McGaugh, J.L., and Roozendaal, B. (2012). Glucocorticoids interact with the hippocamapal endocannabinoid system in impairing retrieval of contextual fear memory. Proc. Natl. Acad. Sci. USA 109, 3504-3509.
2. Batkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey- White, J., Offertaler, L., Mackie, K., Rudd, M.A., Bukoski, R.D., et al. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996-2002.
3. Begg, M., Baydoun, A., Parsons, M.E., and Molleman, A. (2001). Signal transduction of cannabinoid CB1 receptors in a smooth muscle cell line. J. Physiol. 531, 95-104.
4. Bortolato, M., Campolongo, P., Mangieri, R.A., Scattoni, M.L., Frau, R., Trezza, V., La Rana, G., Russo, R., Calignano, A., Gessa, G.L., et al. (2006). Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31, 2652-2659.
5. Burker, E.J., Blumenthal, J.A., Feldman, M., Burnett, R., White, W., Smith, L.R., Croughwell, N., Schell, R., Newman, M., and Reves, J.G. (1995). Depression in male and female patients undergoing cardiac surgery. Br. J. Clin. Psychol. 34 (Pt 1), 119-128.
6. Campolongo, P., Roozendaal, B., Trezza, V., Hauer, D., Schelling, G., McGaugh, J.L., and Cuomo, V. (2009). Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc. Natl. Acad. Sci. USA 106, 4888-4893.
7. Centonze, D., Battistini, L., and Maccarrone, M. (2008). The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr. Pharm. Des. 14, 2370-2342.
8. Chouker, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., Vogeser, M., Thiel, M., and Schelling, G. (2010). Motion sickness, stress and the endocannabinoid system. PLoS One 5, e10752.
9. Cote, M., Matias, I., Lemieux, I., Petrosino, S., Almeras, N., Despres, J.P., and Di Marzo, V. (2007). Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. (Lond.) 31, 692-699.
10. Di Marzo, V., Verrijken, A., Hakkarainen, A., Petrosino, S., Mertens, I., Lundbom, N., Piscitelli, F., Westerbacka, J., Soro-Paavonen, A., Matias, I., et al. (2009). Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur. J. Endocrinol. 161, 715-722.
11. Domschke, K. and Zwanzger, P. (2008). GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets? Curr. Pharm. Des. 14, 3508-3517.
12. Eisenstein, T.K., Meissler, J.J., Wilson, Q., Gaughan, J.P., and Adler, M.W. (2007). Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J. Neuroimmunol. 189, 17-22.
13. Fajardo, G. and Bernstein, D. (2007). Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity. J. Am. Coll. Cardiol. 50, 537-539.
14. Gobbi, G., Bambico, F.R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M.G., Debonnel, G., Duranti, A., et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 102, 18620-18625.
15. Gorzalka, B.B., Hill, M.N., and Hillard, C.J. (2008). Regulation of endocannabinoid signaling by stress: implications for stressrelated affective disorders. Neurosci. Biobehav. Rev. 32, 1152-1160.
16. Hamilton, M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62.
17. Hauer, D., Ratano, P., Morena, M., Scaccianoce, S., Briegel, I., Palmery, M., Cuomo, V., Roozendaal, B., Schelling, G., and Campolongo, P. (2011). Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology 114, 1380-1388.
18. Hemmings, H.C., Jr. and Mackie, K. (2011). The rivers of lethe and mnemosyne converge: propofol and memory consolidation. Anesthesiology 114, 1277-1279.
19. Hill, M.N. and Gorzalka, B.B. (2009). Impairments in endocannabinoid signaling and depressive illness. J. Am. Med. Assoc. 301, 1165-1166.
20. Hill, M.N., Miller, G.E., Ho, W.S., Gorzalka, B.B., and Hillard, C.J. (2008). Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41, 48-53.
21. Hill, M.N., Miller, G.E., Carrier, E.J., Gorzalka, B.B., and Hillard, C.J. (2009). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34, 1257-1268.
22. Hill, M.N., Patel, S., Campolongo, P., Tasker, J.G., Wotjak, C.T., and Bains, J.S. (2010). Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J. Neurosci. 30, 14980-14986.
23. Kapfhammer, H.P., Rothenhausler, H.B., Krauseneck, T., Stoll, C., and Schelling, G. (2004). Posttraumatic stress disorder and health-related quality of life in long-term survivors of acute respiratory distress syndrome. Am. J. Psychiatry 161, 45-52.
24. Kaufmann, I., Schelling, G., Eisner, C., Richter, H.P., Krauseneck, T., Vogeser, M., Hauer, D., Campolongo, P., Chouker, A., Beyer, A., et al. (2008). Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33, 676-685.
25. Kilger, E., Weis, F., Briegel, J., Frey, L., Goetz, A.E., Reuter, D., Nagy, A., Schuetz, A., Lamm, P., Knoll, A., et al. (2003). Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit. Care Med. 31, 1068-1074.
26. Kreutz, S., Koch, M., Bottger, C., Ghadban, C., Korf, H.W., and Dehghani, F. (2009). 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol- sensitive receptors on microglial cells. Glia 57, 286-294.
27. Lourbopoulos, A., Grigoriadis, N., Lagoudaki, R., Touloumi, O., Polyzoidou, E., Mavromatis, I., Tascos, N., Breuer, A., Ovadia, H., Karussis, D., et al. (2011). Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 1390, 126-141.
28. Mach, F. and Steffens, S. (2008). The role of the endocannabinoid system in atherosclerosis. J. Neuroendocrinol. 20 (Suppl 1), 53-57.
29. Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29, 225-232.
30. Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., Hermann, H., Tang, J., Hofmann, C., Zieglgansberger, W., et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534.
31. Mitchell, P.B. and Morris, M.J. (2007). Depression and anxiety with rimonabant. Lancet 370, 1671-1672.
32. Moreira, F.A., Grieb, M., and Lutz, B. (2009). Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23, 133-144.
33. Nissen, S.E., Nicholls, S.J., Wolski, K., Rodes-Cabau, J., Cannon, C.P., Deanfield, J.E., Despres, J.P., Kastelein, J.J., Steinhubl, S.R., Kapadia, S., et al. (2008). Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J. Am. Med. Assoc. 299, 1547-1560.
34. Onaivi, E.S., Ishiguro, H., Gong, J.P., Patel, S., Perchuk, A., Meozzi, P.A., Myers, L., Mora, Z., Tagliaferro, P., Gardner, E., et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. NY Acad. Sci. 1074, 514-536.
35. Pacher, P. (2009). Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler. Thromb. Vasc. Biol. 29, 7-9.
36. Patel, S. and Hillard, C.J. (2008). Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur. J. Neurosci. 27, 2821-2829.
37. Pertwee, R.G. (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict. Biol. 13, 147-159.
38. Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J., and Ghali, W.A. (2011). Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. Br. Med. J. 342, d671.
39. Schelling, G., Richter, M., Roozendaal, B., Rothenhausler, H.B., Krauseneck, T., Stoll, C., Nollert, G., Schmidt, M., and Kapfhammer, H.P. (2003). Exposure to high stress in the intensive care unit may have negative effects on health-related quality-of-life outcomes after cardiac surgery. Crit. Care Med. 31, 1971-1980.
40. Schelling, G., Hauer, D., Azad, S.C., Schmoelz, M., Chouker, A., Schmidt, M., Hornuss, C., Rippberger, M., Briegel, J., Thiel, M., et al. (2006). Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology 104, 273-277.
41. Schmidt, A., Brune, K., and Hinz, B. (2006). Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 20, 336-342.
42. Shohami, E., Cohen-Yeshurun, A., Magid, L., Elgali, M., and Mechoulam, R. (2011). Endocannabinoids and traumatic brain injury. Br. J. Pharmacol 163, 1402-1410.
43. Stoll, C., Schelling, G., Goetz, A.E., Kilger, E., Bayer, A., Kapfhammer, H.P., Rothenhausler, H.B., Kreuzer, E., Reichart, B., and Peter, K. (2000). Health-related quality of life and post-traumatic stress disorder in patients after cardiac surgery and intensive care treatment. J. Thorac. Cardiovasc. Surg. 120, 505-512.
44. Stroobant, N. and Vingerhoets, G. (2008). Depression, anxiety, and neuropsychological performance in coronary artery bypass graft patients: a follow-up study. Psychosomatics 49, 326-331.
45. Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., et al. (2009). Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28-36.
46. Treggiari, M.M., Romand, J.A., Yanez, N.D., Deem, S.A., Goldberg, J., Hudson, L., Heidegger, C.P., and Weiss, N.S. (2009). Randomized trial of light versus deep sedation on mental health after critical illness. Crit. Care Med. 37, 2527-2534.
47. Vickers, S.P. and Kennett, G.A. (2005). Cannabinoids and the regulation of ingestive behaviour. Curr. Drug Targets 6, 215-223.
48. Vogeser, M. and Schelling, G. (2007). Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples. Clin. Chem. Lab. Med. 45, 1023-1025.
49. Vogeser, M., Hauer, D., Christina Azad, S., Huber, E., Storr, M., and Schelling, G. (2006). Release of anandamide from blood cells. Clin. Chem. Lab. Med. 44, 488-491.
50. Weis, F., Beiras-Fernandez, A., Schelling, G., Briegel, J., Lang, P., Hauer, D., Kreth, S., Kaufmann, I., Lamm, P., and Kilger, E. (2009a). Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome. Crit. Care Med. 37, 1685-1690.
51. Weis, F., Beiras-Fernandez, A., Sodian, R., Kaczmarek, I., Reichart, B., Beiras, A., Schelling, G., and Kreth, S. (2009b). Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J. Mol. Cell Cardiol. 48, 1187-1193.
52. Weis, F., Beiras-Fernandez, A., Hauer, D., Hornuss, C., Sodian, R., Kreth, S., Briegel, J., and Schelling, G. (2010). Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery. Br. J. Anaest. 105, 139-144.
53. Wolf, S.A., Tauber, S., and Ullrich, O. (2008). CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr. Pharm. Des. 14, 2266-2278.